Hadlima (adalimumab) is a biologic medicine that helps the pain and swelling of arthritis.
Hadlima is used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Inflammatory Arthritis, Psoriasis, Crohn's Disease, Hidradentitis, Iritis, and other diseases.
Hadlima works by blocking Tumor Necrosis Factor (TNF), a type of signalling protein (called a cytokine), that is involved in systemic inflammation. Hadlima belongs to a class of similar medications called Anti-Tumor Necrosis Factor agents.
Hadlima may be prescribed in combination with other rheumatology medications like methotrexate.
Hadlima is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that is designed to be identical to an existing biologic medication, but is created using a different process.
Hadlima is a biosimilar of Humira. Both medications are known by the same generic name: adalimumab. Biosimilars are often cheaper than the original medication.
Hadlima is available as a subcutaneous (under the skin) injection in one of two forms that can be taken at home: as a pre-filled syringe, and as an autoinjector (pen).
Hadlima usually takes about 2 weeks before patients start to feel its effects. It may take 12 weeks to feel the effect of this medicine.
The manufacturer of Hadlima offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Drug Identification Number (DIN)